Create a free research account to view current pricing and place an order.
Mechanism of action
ARA-290 is an innate repair receptor agonist peptide derived from the tissue-protective domain of erythropoietin. It is researched for neuropathy, inflammatory modulation, endothelial protection, and tissue-protective signaling without erythropoietic activity.
Half-life & pharmacokinetics
Half-life: Short acting.
Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
Research dosing reference
2-4 mg daily in neuropathy/tissue-protective research contexts.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 2 mg | 40 units |
| 4 mg | 80 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Often administered daily; consistency is preferred for neuropathy-oriented protocols.
Beginner escalation
Begin at the lower end and evaluate nerve-symptom response and injection tolerance before increasing.
Side-effect mitigation
Monitor headache, fatigue, injection irritation, flushing, or symptom changes.
Stack compatibility
Pairs with regenerative and mitochondrial pathways; avoid adding multiple neuro/immune-active agents simultaneously.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Acute repair protocols are commonly structured as 2-6 week focused blocks, then reassess pain, mobility, inflammatory response, and tissue objective. Maintenance, if used, should be lower-frequency and objective-driven. Growth Hormone Axis
Frequently asked questions
What is ARA-290 and how does it work?
ARA-290 is an innate repair receptor agonist peptide derived from the tissue-protective domain of erythropoietin. It is researched for neuropathy, inflammatory modulation, endothelial protection, and tissue-protective signaling without erythropoietic activity.
What is the half-life of ARA-290?
ARA-290: Short acting. Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
How is ARA-290 reconstituted for research?
Preferred reconstitution for the 10 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is ARA-290 FDA approved?
No. ARA-290 is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration